Abstract:Background Excessive generation of reactive oxygen species (ROS) in the presence of a defective antioxidant system can induce cellular damage and disrupt normal physiological functions. Several studies have revealed the unfavorable role of ROS in promoting the growth, proliferation, migration, and survival of leukemia cells. In this review study, we summarize the mechanisms of ROS production and its role in leukemogenesis, counteractive effects of antioxidants, and implicate the current ROS-dependent anticancer therapies in acute myeloid leukemia. Body The dysregulation of the redox system is known to play a significant role in the pathogenesis of leukemia. Leukemia cells generate high levels of ROS, which further increases the levels through extra pathways, including mitochondrial deoxyribonucleic mutation, leukemic oncogene activation, increased nicotinamide adenine phosphate hydrogen (NADPH), and cytochrome P450 activities. Aforementioned pathways once activated have shown to promote genomic instability, induce drug resistance to leukemia medical therapy, disease relapse and reduce survival period. The current standard of treatment with chemotherapy employs the pro-oxidant approach to induce apoptosis and promote tumor regression. However, this approach retains several deleterious effects on the subject resulting in degradation of the quality of life. Nevertheless, the addition of an antioxidant as an adjuvant drug to chemotherapy alleviates treatment-related toxicity, increases chemotherapeutic efficacy, and improves survival rates of a patient. Conclusion Acute myeloid leukemia remains a daunting challenge to clinicians. The desire to achieve the maximum benefit of chemotherapy but also improve patient outcomes is investigated. ROS generated through several pathways promotes leukemogenesis, drug resistance, and disease relapse. Chemotherapy, the mainstay of treatment, further upregulates ROS levels. Therefore, the addition of an antioxidant to leukemia medical therapy alleviates toxicity and improves patient outcomes.

Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.

Oxidative Stress Response Induced by Chemotherapy in Leukemia Treatment (Review)

The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications

Oxidative stress is two-sided in the treatment of acute myeloid leukemia

Reactive oxygen species in eradicating acute myeloid leukemic stem cells.

Role of reactive oxygen species in myelodysplastic syndromes

Redox, cysteines, and kinases—A triad sustaining myeloid leukemia

Regulation of Leukemogenesis Via Redox Metabolism

Oxidative Stress Targeted Therapies for the Treatment of Acute Myeloid Leukemia

Targeting Redox Regulation as a Therapeutic Opportunity against Acute Leukemia: Pro-Oxidant Strategy or Antioxidant Approach?

Reactive Oxygen Species Rewires Metabolic Activity in Acute Myeloid Leukemia

Targeting ROS in cancer: rationale and strategies

Survey on the Oxidative Stress Status and the Role of Antioxidants in Acute Myeloid Leukemia Therapy

Oxidative stress in leukemia and antioxidant treatment

Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side

Redox regulation and its emerging roles in cancer treatment

Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.

Redox regulation of cancer metastasis: molecular signaling and therapeutic opportunities.

Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients

Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies

The double-edged roles of ROS in cancer prevention and therapy